Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Equity Ratio (2022 - 2024)

Adial Pharmaceuticals' Equity Ratio history spans 3 years, with the latest figure at 0.88 for Q3 2024.

  • For Q3 2024, Equity Ratio rose 7.44% year-over-year to 0.88; the TTM value through Sep 2024 reached 0.88, up 7.44%, while the annual FY2023 figure was 0.86, 50.84% up from the prior year.
  • Equity Ratio for Q3 2024 was 0.88 at Adial Pharmaceuticals, up from 0.86 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q1 2024 and bottomed at 0.37 in Q1 2023.
  • The 3-year median for Equity Ratio is 0.82 (2023), against an average of 0.76.
  • The largest annual shift saw Equity Ratio plummeted 51.87% in 2023 before it skyrocketed 148.17% in 2024.
  • A 3-year view of Equity Ratio shows it stood at 0.57 in 2022, then skyrocketed by 50.84% to 0.86 in 2023, then grew by 1.67% to 0.88 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Equity Ratio are 0.88 (Q3 2024), 0.86 (Q2 2024), and 0.92 (Q1 2024).